GlassScriptPhysician profile
Daniel Kevin Lavie
NPI 1023374659
$8,401.49
in general payments reported to CMS, 2019-2025
64 companies · $1,385 in 2025
The $1,385 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $873 · 2020: $345 · 2021: $141 · 2022: $1,887 · 2023: $2,376 · 2024: $1,394 · 2025: $1,385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,145 · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,145.33 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $1,221.86 | 2023-2025 | Cabometyx |
| Astrazeneca Pharmaceuticals LP | $557.23 | 2019-2025 | Imfinzi, Calquence, Lynparza |
| Merck Sharp & Dohme LLC | $503.71 | 2019-2025 | Keytruda, Welireg, Reblozyl |
| Celgene Corporation | $487.50 | 2019-2025 | Reblozyl, Pomalyst |
| Pfizer INC. | $458.57 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $452.51 | 2019-2025 | |
| Daiichi Sankyo INC. | $422.63 | 2019-2025 | Enhertu, Datroway, Injectafer |
| Janssen Biotech, INC. | $310.25 | 2019-2025 | Rybrevant, Darzalex, Erleada |
| E.R. Squibb & Sons, L.L.C. | $301.70 | 2019-2025 | Opdivo, Augtyro |
| Genzyme Corporation | $274.70 | 2019-2025 | |
| Abbvie INC. | $255.52 | 2022-2025 | |
| Amgen INC. | $250.00 | 2019-2022 | |
| Eisai INC. | $220.83 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $194.44 | 2019-2024 | Onivyde, Somatuline Depot |
| Genentech USA, INC. | $185.26 | 2019-2024 | Lunsumio, Polivy, Columvi |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Lavie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.